IDH1 and central nervous system neoplasm: Using the WHO classification for CNS tumours (13) we then analysed the GB dataset with respect to IDH1 status, where IDH1-wild type corresponds to primary or de novo GB, and the IDH-mutant corresponds to secondary or progressive GB.